Fecal Microbiota Transplantation in Patients Co-Infected with SARS-CoV2 and Clostridioides difficile
-
Published:2022-12-21
Issue:1
Volume:11
Page:7
-
ISSN:2227-9059
-
Container-title:Biomedicines
-
language:en
-
Short-container-title:Biomedicines
Author:
Boicean Adrian, Neamtu BogdanORCID, Birsan Sabrina, Batar Florina, Tanasescu Ciprian, Dura Horatiu, Roman Mihai DanORCID, Hașegan Adrian, Bratu Dan, Mihetiu Alin, Mohor Călin Ilie, Mohor Cosmin, Bacila Ciprian, Negrea Mihai Octavian, Fleaca Sorin RaduORCID
Abstract
Background: The COVID-19 pandemic has challenged the treatment of Clostridioides Difficile (CD)-infected patients given the increasing number of co-infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, fecal microbiota transplantation (FMT) shows promise in modulating the immune system’s function and alleviating the burdens associated with this condition. Methods: To achieve this goal, we performed a comparative, retrospective, single-center study on 86 patients (admitted between January 2020 and March 2022). We based our approach on specific inclusion criteria: 1. The study group included 46 co-infected patients (COVID-19 and CD) receiving antibiotics and FMT; 2. In the control group, 40 co-infected patients received antibiotics only. Our results showed no significant group differences in terms of gender, age, risk factors such as cardiovascular and neurological diseases, type 2 diabetes, and obesity (p > 0.05), or in pre-treatment inflammatory status, evaluated by white blood cell (WBC) count and C-reactive protein (CRP) levels. We report a significant decrease in inflammatory syndrome (CRP, WBC) in coinfected patients receiving FMT in addition to antibiotics (p < 0.05), with a lower relapse rate and mitigation of cramping and abdominal pain (91.3%). In addition, a higher level of fibrinogen, persistent moderate abdominal pain (82.5%), and a significantly higher CD infection relapse rate (42.5%) were recorded in co-infected patients treated only with antibiotics (p < 0.05). Conclusion: Our study provides new data to support the multiple benefits of FMT in the case of COVID-19 and CD co-infection by improving patients’ quality of life and inflammatory syndrome.
Funder
Ministry of Research, Innovation, and Digitization
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference53 articles.
1. Did the severe acute respiratory syndrome-coronavirus 2 pandemic cause an endemic Clostridium difficile infection?;Cojocariu;World J. Clin. Cases,2021 2. Marinescu, A., Laza, R., Musta, V.F., Cut, T.G., Dumache, R., Tudor, A., Porosnicu, M., Lazureanu, V.E., and Licker, M. (2021). Clostridium Difficile and COVID-19: General Data, Ribotype, Clinical Form, Treatment-Our Experience from the Largest Infectious Diseases Hospital in Western Romania. Medicina, 57. 3. Alterations in microbiota of patients with COVID-19: Potential mechanisms and therapeutic interventions;Wang;Sig. Transduct. Target. Ther.,2022 4. Bacterial and Fungal Gut Dysbiosis and Clostridium difficile in COVID-19: A Review;Miller;J. Clin. Gastroenterol.,2022 5. Ramzan, K., Shafiq, S., Raees, I., Mustafa, Z.U., Salman, M., Khan, A.H., Meyer, J.C., and Godman, B. (2022). Co-Infections, Secondary Infections, and Antimicrobial Use in Patients Hospitalized with COVID-19 during the First Five Waves of the Pandemic in Pakistan; Findings and Implications. Antibiotics, 11.
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|